Literature DB >> 19937991

A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo.

Sarah Parker Read1, Siobhan M Cashman, Rajendra Kumar-Singh.   

Abstract

BACKGROUND: We have previously shown that a novel synthetic peptide for ocular delivery (POD) can efficiently compact DNA and deliver it to cells in vitro. This observation prompted us to develop use of POD as a nonviral vector in vivo.
METHODS: POD peptide was modified using poly(ethylene) glycol (PEG-POD) and used to compact DNA into nanoparticles that were then analysed using electron microscopy, dynamic light scattering, and fluorescent labeling. Transfection efficiency and localization were determined 48 h post-injection into the subretinal space of the mouse eye using luciferase and LacZ, respectively. Efficiency of ocular transfection was compared to two other PEGylated peptides: PEG-TAT and PEG-CK30.
RESULTS: PEG-POD can compact DNA and form discrete nanoparticles of approximately 136 nm that can penetrate and transduce the retinal pigment epithelium (RPE) in vivo. PEG-POD significantly increased expression of plasmid DNA by 215-fold, PEG-TAT by 56.52-fold, and PEG-CK30 by 24.73-fold relative to DNA injected alone. In all cases beta-galactosidase was observed primarily in the RPE layer after subretinal injection. Electrophysiological analyses of PEG-POD transduced retina indicates an absence of PEG-POD-mediated toxicity. PEG-POD can protect plasmid DNA from DNaseI digestion, resulting in significant transfection of the lung after intravenous injection in mice.
CONCLUSIONS: PEG-POD was found to significantly increase gene delivery relative to both DNA alone and other pegylated peptides. These findings highlight the use of pegylated peptides, and specifically PEG-POD, as novel gene delivery vectors. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19937991      PMCID: PMC4145735          DOI: 10.1002/jgm.1415

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  29 in total

1.  Rapid quantification of DNase I activity in one-microliter serum samples.

Authors:  Haruo Takeshita; Tamiko Nakajima; Kouichi Mogi; Yasushi Kaneko; Toshihiro Yasuda; Reiko Iida; Koichiro Kishi
Journal:  Clin Chem       Date:  2004-02       Impact factor: 8.327

2.  Nanoparticles of compacted DNA transfect postmitotic cells.

Authors:  Ge Liu; DeShan Li; Murali K Pasumarthy; Tomasz H Kowalczyk; Christopher R Gedeon; Susannah L Hyatt; Jennifer M Payne; Timothy J Miller; Peter Brunovskis; Tamara L Fink; Osman Muhammad; Robert C Moen; Richard W Hanson; Mark J Cooper
Journal:  J Biol Chem       Date:  2003-06-14       Impact factor: 5.157

3.  Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins.

Authors:  W C Shen; H J Ryser
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

4.  Ocular cell transfection with the human basic fibroblast growth factor gene delays photoreceptor cell degeneration in RCS rats.

Authors:  M Neuner-Jehle; L V Berghe; S Bonnel; Y Uteza; F Benmeziane; J S Rouillot; D Marchant; A Kobetz; J L Dufier; M Menasche; M Abitbol
Journal:  Hum Gene Ther       Date:  2000-09-01       Impact factor: 5.695

5.  Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo.

Authors:  Assem-Galal Ziady; Christopher R Gedeon; Timothy Miller; William Quan; Jennifer M Payne; Susannah L Hyatt; Tamara L Fink; Osman Muhammad; Sharon Oette; Tomasz Kowalczyk; Murali K Pasumarthy; Robert C Moen; Mark J Cooper; Pamela B Davis
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

6.  Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung.

Authors:  Assem-Galal Ziady; Christopher R Gedeon; Osman Muhammad; Virginia Stillwell; Sharon M Oette; Tamara L Fink; Will Quan; Tomasz H Kowalczyk; Susannah L Hyatt; Jennifer Payne; Angela Peischl; J E Seng; Robert C Moen; Mark J Cooper; Pamela B Davis
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

7.  Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways.

Authors:  Irina A Ignatovich; Ella B Dizhe; Anna V Pavlotskaya; Boris N Akifiev; Sergey V Burov; Sergey V Orlov; Andrej P Perevozchikov
Journal:  J Biol Chem       Date:  2003-07-25       Impact factor: 5.157

8.  PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.

Authors:  Swaroop Mishra; Paul Webster; Mark E Davis
Journal:  Eur J Cell Biol       Date:  2004-04       Impact factor: 4.492

9.  Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells.

Authors:  Carsten Rudolph; Christian Plank; James Lausier; Ulrike Schillinger; Rainer H Müller; Joseph Rosenecker
Journal:  J Biol Chem       Date:  2003-01-08       Impact factor: 5.157

10.  Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin.

Authors:  Leslie N Johnson; Siobhan M Cashman; Sarah Parker Read; Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2009-09-03       Impact factor: 1.886

View more
  12 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Nanoparticles in the ocular drug delivery.

Authors:  Hong-Yan Zhou; Ji-Long Hao; Shuang Wang; Yu Zheng; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

3.  Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells.

Authors:  Adarsha Koirala; Rasha S Makkia; Mark J Cooper; Muna I Naash
Journal:  Biomaterials       Date:  2011-09-01       Impact factor: 12.479

4.  Genomic form of rhodopsin DNA nanoparticles rescued autosomal dominant Retinitis pigmentosa in the P23H knock-in mouse model.

Authors:  Rajendra Narayan Mitra; Min Zheng; Ellen R Weiss; Zongchao Han
Journal:  Biomaterials       Date:  2017-12-05       Impact factor: 12.479

Review 5.  Nanoparticle-motivated gene delivery for ophthalmic application.

Authors:  Rajendra Narayan Mitra; Min Zheng; Zongchao Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-06-22

6.  POD nanoparticles expressing GDNF provide structural and functional rescue of light-induced retinal degeneration in an adult mouse.

Authors:  Sarah P Read; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

7.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

8.  Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics.

Authors:  R K Khar; G K Jain; M H Warsi; N Mallick; S Akhter; S A Pathan; F J Ahmad
Journal:  Indian J Pharm Sci       Date:  2010-11       Impact factor: 0.975

Review 9.  Vector platforms for gene therapy of inherited retinopathies.

Authors:  Ivana Trapani; Agostina Puppo; Alberto Auricchio
Journal:  Prog Retin Eye Res       Date:  2014-08-12       Impact factor: 21.198

10.  Extended duration of transgene expression from pegylated POD nanoparticles enables attenuation of photoreceptor degeneration.

Authors:  Christina Binder; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.